12. October 2017

Poor aqueous solubility leading to poor oral bioavailability is a bottle neck in the development of many new drug candidates; particularly the BCS class II-IV drugs. These molecules are difficult to formulate using conventional approaches and are associated with numerous formulation related performance issues.